Trabectedin for advanced soft tissue sarcomas: optimizing use
Alison Reid, Juan Martin-Liberal, Charlotte Benson Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK Abstract: Patients with locally advanced or metastatic soft tissue sarcoma have a poor outlook with median survival in the order of 1 year.There is therefore an urgent need for novel agents to impact this disease.Trabectedin is one su